A detailed history of Chesley Taft & Associates LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Chesley Taft & Associates LLC holds 4,805 shares of GILD stock, worth $596,252. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,805
Previous 3,274 46.76%
Holding current value
$596,252
Previous $362,000 47.24%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 07, 2025

BUY
$108.22 - $120.47 $165,684 - $184,439
1,531 Added 46.76%
4,805 $533,000
Q2 2025

Jul 09, 2025

BUY
$96.91 - $113.0 $94,390 - $110,062
974 Added 42.35%
3,274 $362,000
Q1 2025

Apr 10, 2025

BUY
$89.14 - $117.41 $205,022 - $270,043
2,300 New
2,300 $257,000
Q4 2017

Jan 10, 2018

SELL
$71.15 - $83.52 $355,750 - $417,600
-5,000 Closed
0 $0
Q3 2017

Oct 13, 2017

BUY
$72.11 - $85.47 $360,550 - $427,350
5,000
5,000 $405,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $156B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Chesley Taft & Associates LLC Portfolio

Follow Chesley Taft & Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chesley Taft & Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chesley Taft & Associates LLC with notifications on news.